COMPASS Pathways (CMPS) Q1 2026 earnings summary

Executive summary

• Achieved primary endpoints in pivotal Phase 3 trials for COMP360 in treatment-resistant depression (TRD), demonstrating rapid and durable efficacy in over 1,000 participants, with a generally well-tolerated safety profile.

• FDA granted rolling NDA submission and review for COMP360 in TRD, with final NDA submission on track for Q4 2026 and launch readiness targeted by year-end.

• Awarded a Commissioner's National Priority Voucher (CNPV), potentially accelerating FDA review to 1–2 months; White House Executive Order supports expedited DEA review and rescheduling for psychedelic treatments.

• Advanced COMP360 development for PTSD, with late-stage trial design finalized, IND accepted by FDA, and leveraging existing infrastructure and VA collaborations.

Financial highlights

• Net income for Q1 2026 was $91.2 million, compared to a net loss of $17.9 million in Q1 2025, primarily due to a $130.9 million non-cash gain on warrant fair value adjustment.

• Operating expenses for Q1 2026 totaled $42.9 million, down from $49.6 million year-over-year, with R&D at $26.5 million and G&A at $16.4 million.

• Cash and cash equivalents rose to $466 million as of March 31, 2026, up from $149.6 million at year-end 2025.

• Debt increased to $50.5 million from $31.6 million over the same period.

Outlook and guidance

• Cash position expected to fund operations and capital expenditures into 2028, excluding potential proceeds from outstanding PIPE warrants.

• 26-week data from COMP006 expected in early Q3 2026; final NDA submission remains on track for Q4 2026.

• Launch readiness initiatives underway, including commercial team buildout, payer engagement, and infrastructure scaling.